167 related articles for article (PubMed ID: 34645185)
1. [Clinical study of circulating tumor cells in monitoring the efficacy of neoadjuvant immunotherapy for non-small cell lung cancer].
Li YJ; Chen H; Liao JF; Yuan JL; Chen T; Zhu J
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Feb; 55(2):233-238. PubMed ID: 34645185
[No Abstract] [Full Text] [Related]
2. A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy.
Wang F; Yang H; Chen W; Ruan L; Jiang T; Cheng L; Jiang H; Fang M
Curr Probl Cancer; 2024 Jun; 50():101098. PubMed ID: 38704949
[TBL] [Abstract][Full Text] [Related]
3. [Impact of neoadjuvant immunotherapy on pulmonary function and perioperative outcomes in patients with resectable non-small cell lung cancer].
Zhu Y; Li JQ; Chang Q; Qiang HP; Lu JH; Feng H; Shen YC; Qian JL; Chu TQ
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):393-398. PubMed ID: 35144337
[No Abstract] [Full Text] [Related]
4. Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Sun W; Liu X; Wang C; Jiang Y; Lin D
Ann Diagn Pathol; 2024 Apr; 69():152268. PubMed ID: 38301396
[TBL] [Abstract][Full Text] [Related]
5. [Value of dual-energy CT-based volumetric iodine-uptake in the evaluation of chemotherapy efficacy in advanced gastric cancer].
Chen LF; Fu GZ; Huang DP; Man Y; Jin Y; Dong QT; Huang YB; Chen YC; Wang HQ
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Oct; 22(10):977-983. PubMed ID: 31630497
[No Abstract] [Full Text] [Related]
6. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
[No Abstract] [Full Text] [Related]
7. Evaluation of sensitivity and specificity of CanPatrol™ technology for detection of circulating tumor cells in patients with non-small cell lung cancer.
Li J; Liao Y; Ran Y; Wang G; Wu W; Qiu Y; Liu J; Wen N; Jing T; Wang H; Zhang S
BMC Pulm Med; 2020 Oct; 20(1):274. PubMed ID: 33081780
[TBL] [Abstract][Full Text] [Related]
8. Is response evaluation criteria in solid tumors (RECIST) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced NSCLC?
Xu Y; Ma D; Qin Y; Li S; Li J; Jiang Y; Wang M; Xu Y; Zhao J; Chen M; Cheng W; Hu K; Liu H
Thorac Cancer; 2023 Jun; 14(17):1635-1639. PubMed ID: 37094918
[TBL] [Abstract][Full Text] [Related]
9. Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD).
Zeng A; Yin Y; Xu Z; Abuduwayiti A; Yang F; Shaik MS; Wang C; Chen K; Wang C; Fang X; Dai J
BMC Cancer; 2024 Mar; 24(1):396. PubMed ID: 38553708
[TBL] [Abstract][Full Text] [Related]
10. Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study.
Zhou S; Liu Y; Liu K; Zhang J; Liang H; Wu Y; Ye H; Liang Y; Zhang J; Huang W
Front Immunol; 2023; 14():1343504. PubMed ID: 38187385
[TBL] [Abstract][Full Text] [Related]
11. Innovative method using circulating tumor cells for prediction of the effects of induction therapy on locally advanced non-small cell lung cancer.
Tarumi S; Gotoh M; Kasai Y; Matsuura N; Okuda M; Go T; Ishikawa S; Yokomise H
J Cardiothorac Surg; 2013 Jul; 8():175. PubMed ID: 23856305
[TBL] [Abstract][Full Text] [Related]
12. Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis.
Chen Y; Qin J; Wu Y; Lin Q; Wang J; Zhang W; Liang F; Hui Z; Zhao M; Wang J
Int J Surg; 2023 Sep; 109(9):2794-2807. PubMed ID: 37247009
[TBL] [Abstract][Full Text] [Related]
13. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
Singh C; Qian JM; Yu JB; Chiang VL
J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
[TBL] [Abstract][Full Text] [Related]
14. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
[TBL] [Abstract][Full Text] [Related]
15. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with
Chemotherapy in Resectable Non-small Cell Lung Cancer].
Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing.
Hu J; Zhang L; Xia H; Yan Y; Zhu X; Sun F; Sun L; Li S; Li D; Wang J; Han Y; Zhang J; Bian D; Yu H; Chen Y; Fan P; Ma Q; Jiang G; Wang C; Zhang P
Genome Med; 2023 Mar; 15(1):14. PubMed ID: 36869384
[TBL] [Abstract][Full Text] [Related]
17. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
Jia XH; Xu H; Geng LY; Jiao M; Wang WJ; Jiang LL; Guo H
Lung Cancer; 2020 Sep; 147():143-153. PubMed ID: 32717571
[TBL] [Abstract][Full Text] [Related]
19. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.
Shen J; Gu L; Qi Y; Yao Y; Lu S; Chen Z
Front Immunol; 2023; 14():1268251. PubMed ID: 37818382
[TBL] [Abstract][Full Text] [Related]
20. An open, observational, three-arm clinical study of 2-3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis.
Gu L; Wang X; Sun Y; Xu Y; Niu X; Zhao R; Yao Y; Jian H; Han Y; Wei J; Chen Z; Lu S
Front Immunol; 2022; 13():938269. PubMed ID: 36059450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
